Loading
A phase 3 trial of Tislelizumab, Cisplatin, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by BeiGene, active and no longer recruiting.
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT04379635 by BeiGene, with 453 participants enrolled, started 2020-05-29 and due to reach its primary completion in 2023-08-21. Interventions recorded: Tislelizumab, Cisplatin injection, Paclitaxel injection, Pemetrexed Disodium, Placebos. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
A second publication from the trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT04379635 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Pemetrexed, Paclitaxel / nab-paclitaxel.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.